Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
RNA Biol. 2024 Jan;21(1):1-15. doi: 10.1080/15476286.2023.2290769. Epub 2023 Dec 19.
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD), which affects approximately 25% of the global population, is an urgent health issue leading to various metabolic comorbidities. Circular RNAs (circRNAs), covalently closed RNA molecules, are characterized by ubiquity, diversity, stability, and conservatism. Indeed, they participate in various biological processes via distinct mechanisms that could modify the natural history of NAFLD. In this review, we briefly introduce the biogenesis, characteristics, and biological functions of circRNAs. Furthermore, we summarize circRNAs expression profiles in NAFLD by intersecting seven sequencing data sets and describe the cellular roles of circRNAs and their potential advantages as biomarkers of NAFLD. In addition, we emphatically discuss the exosomal non-coding RNA sorting mechanisms and possible functions in recipient cells. Finally, we extensively discuss the potential application of targeting disease-related circRNAs and competing endogenous RNA networks through gain-of-function and loss-of-function approaches in targeted therapy of NAFLD.
PMID:38113132 | DOI:10.1080/15476286.2023.2290769
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Competitive adsorption of microRNA-532-3p by circular RNA SOD2 activates Thioredoxin Interacting Protein/NLR family pyrin domain containing 3 pathway and promotes pyroptosis of non-alcoholic fatty hepatocytes RNA modifications in the progression of liver diseases: from fatty liver to cancer RNA modifications in the progression of liver diseases: from fatty liver to cancer Emerging roles of RNA-binding proteins in fatty liver disease Unveiling the role of disulfidptosis-related genes in the pathogenesis of non-alcoholic fatty liver disease Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine The gut-liver axis in fatty liver disease: role played by natural products Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics Natural compounds proposed for the management of non-alcoholic fatty liver disease From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step? Noncoding RNA Lipotherapeutics: A Promising Breakthrough in Pulmonary Hypertension Treatment Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features Mitochondrial ACSS1-K635 acetylation knock-in mice exhibit altered metabolism, cell senescence, and nonalcoholic fatty liver disease Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome Role of the angiopoietin-like protein family in the progression of NAFLD Crosstalk in extrahepatic and hepatic system in NAFLD/NASH Crosstalk in extrahepatic and hepatic system in NAFLD/NASH TET3 boosts hepatocyte autophagy and impairs non-alcoholic fatty liver disease by increasing ENPP1 promoter hypomethylation A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury Management of Cardiovascular Risk in the Non-alcoholic Fatty Liver Disease Setting Unraveling the relationship between histone methylation and nonalcoholic fatty liver disease Role of FXR in the development of NAFLD and intervention strategies of small molecules Hericium erinaceus polysaccharides ameliorate nonalcoholic fatty liver disease via gut microbiota and tryptophan metabolism regulation in an aged laying hen model Synthesis and biological evaluation of the novel chrysin prodrug for non-alcoholic fatty liver disease treatment Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway Exploring Bile-Acid Changes and Microflora Profiles in Chicken Fatty Liver Disease Model Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD) PINK1/Park2-Mediated Mitophagy Relieve Non-Alcoholic Fatty Liver Disease Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action Nonalcoholic Fatty Liver Disease and Ethnicity: Lessons Learned from the Arab Population in Israel Multifunctional role of oral bacteria in the progression of non-alcoholic fatty liver disease Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1 Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect Pro- and anti-inflammatory cytokines are the game-changers in childhood obesity-associated metabolic disorders (diabetes and non-alcoholic fatty liver diseases) Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches Deficiency of ADAR2 ameliorates metabolic-associated fatty liver disease via AMPK signaling pathways in obese mice Six-gene prognostic signature for non-alcoholic fatty liver disease susceptibility using machine learning From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients Supplementation of Micro- and Macronutrients-A Role of Nutritional Status in Non-Alcoholic Fatty Liver Disease Integrating network pharmacology and experimental validation reveals therapeutic effects of D-mannose on NAFLD through mTOR suppression Linking Non-alcoholic Fatty Liver Disease Severity With Metabolic Syndrome Features: An Integrative Study on Clinical and Radiological Fronts Linking Non-alcoholic Fatty Liver Disease Severity With Metabolic Syndrome Features: An Integrative Study on Clinical and Radiological Fronts FGL1 and FGL2: emerging regulators of liver health and disease Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis Loss of GPR75 protects against non-alcoholic fatty liver disease and body fat accumulation 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study Roles and Mechanisms of Choline Metabolism in Nonalcoholic Fatty Liver Disease and Cancers Integrated spatial metabolomics and transcriptomics decipher the hepatoprotection mechanisms of wedelolactone and demethylwedelolactone on non-alcoholic fatty liver disease Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt Bacteroides and NAFLD: pathophysiology and therapy
Evidence Blueprint
Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Circular RNAs in non-alcoholic fatty liver disease: Functions and clinical significance
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease Whole Transcriptome Sequencing of Peripheral Blood Identifies the Alzheimer's Disease-Related circRNA-miRNA-lncRNA Pathway Competitive adsorption of microRNA-532-3p by circular RNA SOD2 activates Thioredoxin Interacting Protein/NLR family pyrin domain containing 3 pathway and promotes pyroptosis of non-alcoholic fatty hepatocytes RNA modifications in the progression of liver diseases: from fatty liver to cancer RNA modifications in the progression of liver diseases: from fatty liver to cancer Interaction between SIRT1 and non-coding RNAs in different disorders Emerging roles of RNA-binding proteins in fatty liver disease Cornerstone Cellular Pathways for Metabolic Disorders and Diabetes Mellitus: Non-Coding RNAs, Wnt Signaling, and AMPK Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease Unveiling the role of disulfidptosis-related genes in the pathogenesis of non-alcoholic fatty liver disease Metabolic dysfunction: The silenced connection with fatty liver disease Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review The role of Sirtuin 2 in liver - An extensive and complex biological process Berberine prevents NAFLD and HCC by modulating metabolic disorders Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review Decoding m6A mRNA methylation by reader proteins in liver diseases Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD) Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy Gasotransmitters in non-alcoholic fatty liver disease: just the tip of the iceberg Macrophage heterogeneity role in NAFLD and NASH disease progression Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease The gut-liver axis in fatty liver disease: role played by natural products Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies The levels of IL1RN is a factor influencing the onset of rheumatoid arthritis in non-alcoholic fatty liver disease Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease Unique Genetic Features of Lean NAFLD: A Review of Mechanisms and Clinical Implications Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages Cell-type specific role of autophagy in the liver and its implications in non-alcoholic fatty liver disease Non-Alcoholic Fatty Liver Disease as an Emerging Risk Factor for Heart Failure Alternative splicing: a bridge connecting NAFLD and HCC Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment MASLD: a systemic metabolic disorder with cardiovascular and malignant complications Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics Natural compounds proposed for the management of non-alcoholic fatty liver disease Non-coding RNAs/DNMT3B axis in human cancers: from pathogenesis to clinical significance Adverse Maternal Environments Perturb Hepatic DNA Methylome and Transcriptome Prior to the Adult-Onset Non-Alcoholic Fatty Liver Disease in Mouse Offspring lncRNA and circRNA expression profiles in the hippocampus of Aβ25‑35‑induced AD mice treated with Tripterygium glycoside The challenging role of micro-RNAs in non-alcoholic fatty liver disease in children with obesity: is it time for a new era? The role of N6-methyladenosine methyltransferase RBM15 in non-alcoholic fatty liver disease From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies Regulation of neuronal circHomer1 biogenesis by PKA/CREB/ERK-mediated pathways and effects of glutamate and dopamine receptor blockade Beyond ribosome biogenesis: noncoding nucleolar RNAs in physiology and tumor biology Lauric acid attenuates hepato-metabolic complications and molecular alterations in high-fat diet-induced Non-alcoholic Fatty Liver Disease in rats Invariant natural killer T cells drive hepatic homeostasis in Non-alcoholic fatty liver disease via sustained IL-10 expression in CD170+ Kupffer cells Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets The Correlation Between Serum Copper and Non-alcoholic Fatty Liver Disease in American Adults: an Analysis Based on NHANES 2011 to 2016 Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD From complement to complosome in non-alcoholic fatty liver disease: When location matters Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step? Gut Microbiota in Patients with Non-Alcoholic Fatty Liver Disease without Type 2 Diabetes: Stratified by Body Mass Index Leukocyte cell-derived chemotaxin 2 correlates with pediatric non-alcoholic fatty liver disease Noncoding RNA Lipotherapeutics: A Promising Breakthrough in Pulmonary Hypertension Treatment Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update